Grail

The companies on this list are mobilizing the creative tools of capitalism to help solve social problems.

CTW 2023-GRAIL

Early detection and diagnosis can reduce cancer mortality rates by 26%. Health care startup Grail aims to make that reduction more common with Galleri, a multicancer early detection (MCED) blood test that can detect a shared cancer signal across more than 50 types of cancers. Galleri complements physician-recommended single-cancer screenings and can help detect cancer in its early stages, when treatment is more likely to be successful.<br />
<br />
Since releasing Galleri in 2021, Grail has had over 100,000 physician orders for the test. The initiative has yet to turn a profit, but its revenue doubled in the first quarter of 2023 year over year, largely driven by test volume growth. MCED tests are not yet FDA-approved. However, Galleri was granted FDA Breakthrough Device designation in 2019, which expedites the approval process so that more patients can access the technology sooner.

Grail

Grail in Fortune Rankings